Microcap Ledger Acumen Pharmaceuticals, Inc. $ABOS
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Newton, MA
- Fiscal year end
- December 31
- Shares outstanding
- 72,317,285 [10-Q 2026-08-12]
What the company doesAI summary of filing
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for Alzheimer's disease. The company's lead product candidate is sabirnetug (ACU193), a monoclonal antibody designed to selectively target soluble amyloid-beta oligomers, which the company believes are a key underlying cause of AD. Sabirnetug is currently in Phase 2 clinical testing (ALTITUDE-AD trial), with top-line results expected in late 2026. The company is also investigating an enhanced brain delivery therapy platform in collaboration with JCR Pharmaceuticals and developing a subcutaneous formulation of sabirnetug with Halozyme. The company has no product revenue and operates through research collaborations, licensing agreements, and clinical development programs. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$53.45M | −$42.20M | $59.44M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | — | −$121.33M | −$115.54M | $53.99M | [10-K 2026-03-26] |
| FY ended Dec 2024 | — | −$102.33M | −$86.22M | $35.63M | [10-K 2026-03-26] |
- Quarterly cash burn
- −$21.10M
- Cash runway Estimate
- ~8.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 60,079,778 | [10-Q 2024-11-12] |
| 2025-03-24 | 60,573,425 | [10-K 2025-03-27] |
| 2025-05-07 | 60,573,425 | [10-Q 2025-05-13] |
| 2025-08-08 | 60,573,425 | [10-Q 2025-08-12] |
| 2025-11-07 | 60,573,425 | [10-Q 2025-11-12] |
| 2026-03-20 | 72,212,758 | [10-K 2026-03-26] |
| 2026-05-07 | 72,227,580 | [10-Q 2026-05-12] |
| 2026-08-07 | 72,317,285 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2026-03-26; declared effective 2026-04-01 [S-3 2026-03-26]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-17 | Porter Derrell | exercise | 13,040 | $1.07 | [4 2026-06-17] |
| 2026-06-17 | Porter Derrell | sell | 13,040 | $2.33 | [4 2026-06-17] |
| 2026-06-16 | Porter Derrell | sell | 12,800 | $2.33 | [4 2026-06-17] |
| 2026-06-15 | Porter Derrell | exercise | 6,460 | $1.07 | [4 2026-06-17] |
| 2026-06-15 | Porter Derrell | sell | 6,460 | $2.35 | [4 2026-06-17] |
| 2026-06-09 | Fountain Nathan B | sell | 6,400 | $2.23 | [4 2026-06-10] |
| 2026-06-03 | Ra Capital Management, L.P. | grant | 35,500 | — | [4 2026-06-05] |
| 2026-06-03 | Fountain Nathan B | grant | 35,500 | — | [4 2026-06-05] |
| 2026-06-03 | Drapkin Kimberlee C | grant | 35,500 | — | [4 2026-06-05] |
| 2026-06-03 | Stalfort John A Iii | grant | 35,500 | — | [4 2026-06-05] |
| 2026-06-03 | Porter Derrell | grant | 35,500 | — | [4 2026-06-05] |
| 2026-06-03 | Ives Jeffrey L. | grant | 35,500 | — | [4 2026-06-05] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-16 | 8-K | Regulation FD disclosure |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-06-16 | 8-K | Regulation FD disclosure; Other events |
| 2026-06-03 | 8-K | Shareholder vote results |
| 2026-05-12 | 10-Q | Quarterly report |
| 2026-05-12 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-04-23 | DEF 14A | Proxy statement |
| 2026-04-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-04-01 | 424B3 | Prospectus or prospectus supplement |
| 2026-03-26 | S-3 | Registration statement |
| 2026-03-26 | 10-K | Annual report |
Alerts for $ABOS
Email me when Acumen Pharmaceuticals, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.